These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 34370275

  • 1. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P.
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [Abstract] [Full Text] [Related]

  • 2. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Jack D, Vermersch P.
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
    Signori A, Ponzano M, Alexandri N, Giovannoni G, Sormani MP.
    Eur J Neurol; 2022 Jul; 29(7):2144-2147. PubMed ID: 35258154
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
    Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A.
    Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 14. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K.
    Neurol Neurochir Pol; 2023 Jan 01; 57(4):371-378. PubMed ID: 37490356
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Value Health; 2019 Jul 01; 22(7):772-776. PubMed ID: 31277823
    [Abstract] [Full Text] [Related]

  • 17. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W, Amin A, Ashton L, Herbert A.
    Mult Scler Relat Disord; 2023 Nov 01; 79():104951. PubMed ID: 37639781
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 01; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K.
    Mult Scler; 2018 Oct 01; 24(11):1461-1468. PubMed ID: 28817997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.